Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or
Standard; Transfer of Listing.
On February 15, 2023, Deep Medicine Acquisition Corp., a Delaware corporation
(the "Company") received approval (the "Approval") from the Nasdaq Listing
Qualifications Department of the Nasdaq Stock Market (the "Nasdaq") that the
Company's application to transfer the listing of its Class A common stock and
rights from the Nasdaq Global Market to the Nasdaq Capital Market has been
approved. The Class A common stock and rights will be transferred to the Nasdaq
Capital Market at the opening of business on February 17, 2023. The Company's
Class A common stock and rights will continue to trade under the symbol "DMAQ"
and "DMAQR," respectively. The Nasdaq Capital Market operates in substantially
the same manner as the Nasdaq Global Market, and listed companies must meet
certain financial requirements and comply with Nasdaq's corporate governance
requirements.
As previously disclosed, the Company received a letter from Nasdaq on January
22, 2023 indicating that the Company, following the stockholder redemptions at
its last stockholder meeting, is not in compliance with Listing Rule 5450(b)(2),
due to the Company's failure to meet the minimum 1,100,000 publicly held shares
requirement for continued listing on the Nasdaq Global Market. Upon the transfer
of listing of the Company's securities on the Nasdaq Capital Market on February
17, 2023, such deficiency would be resolved.
On February 16, 2023, the Company issued a press release announcing its listing
transfer to the Nasdaq Capital Market, which is attached as Exhibit 99.1 to this
current report on Form 8-K and is incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
Exhibit No. Description of Exhibit
99.1 Press release dated February 16, 2023.
104 Cover Page Interactive Data File (embedded within the Inline XBRL
document)
© Edgar Online, source Glimpses